The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.
The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.
In documents posted Monday, the FDA reiterated its longstanding position that drugmaker Brainstorm s lone study doesn t provide convincing evidence that its stem cell-based therapy helps patients with ALS, or amyotrophic lateral sclerosis.
The FDA is meeting this week to consider NurOwn, a much-debated treatment for Lou Gehrig’s disease. The agency says the treatment hasn't been shown to work.